Daniel Feltrin is a well-rounded leader in the field of haematology and oncology, currently serving as the Franchise Head for Haemato-Oncology. With experience at Bristol-Myers Squibb as a Clinical Project Manager and Medical Science Manager, Daniel has developed a strong foundation in medical affairs. Their tenure at AstraZeneca included roles such as Medical Affairs Manager and Therapeutic Area Lead, where they significantly contributed to the launch of Acalabrutinib in Switzerland. Daniel holds a PhD in Neurobiology from the University of Basel and has completed advanced studies in Clinical Trial Practice and Management. They are recognized for their commitment to talent attraction and retention within the industry.
This person is not in any teams
This person is not in any offices